Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Pharmaceutical TechnologyEarly data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.HematologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO26: In vivo oncology approaches continue to show promiseNext: Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
